Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
7 evidence topics · 8 sources
RAPIDe-3: concomitant long-term prophylaxis permitted
RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack
| Long-term prophylaxis | Deucrictibant (n=101) | Placebo (n=100) | Overall participants (n=113) |
|---|---|---|---|
| Any concomitant long-term prophylaxis | “20 (20%)” | “24 (24%)” | “26 (23%)” |
| Lanadelumab | “8 (8%)” | “10 (10%)” | “11 (10%)” |
| Berotralstat | “5 (5%)” | “7 (7%)” | “7 (6%)” |
| C1-esterase inhibitor | “4 (4%)” | “5 (5%)” | “5 (4%)” |
| Danazol | “3 (3%)” | “2 (2%)” | “3 (3%)” |